Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Avita Medical Ltd. (OTC: AVMXY).

Full DD Report for AVMXY

Recent News from (OTC: AVMXY)

RECELL pivotal trial meets co-primary endpoints and shows reduction in donor skin requirements
AVITA Medical ( OTCQX:AVMXY ) has achieved co -primary endpoint in its clinical trial in the treatment of third-degree burns with the RECELL Autologous Cell Harvesting Device, demonstrating a significant reduction in donor skin requirements versus standard of care while achieving comparabl...
Source: SeekingAlpha
Date: April, 16 2018 07:39
RECELL® Pivotal Trial in Third-Degree Burns Meets Co-Primary Endpoints and Shows Statistically Significant Reduction in Donor Skin Requirements
Presentation today at American Burn Association Meeting highlights potential of RECELL to improve patient care in severe burns AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that its pivotal, controlled clinical trial in the treatment of deep full-thickness (third-degree) burn...
Source: Business Wire
Date: April, 15 2018 22:09
RECELL® Study in Facial Burns Shows Excellent Cosmetic Outcomes
Two presentations today at American Burn Association Meeting highlight potential of RECELL to improve patient care in difficult-to-treat burns AVITA Medical (ASX: AVH , OTCQX: AVMXY ) announced today results from a clinical study highlighting the potential benefits of the RECELL ...
Source: Business Wire
Date: April, 12 2018 19:45
AVITA Medical Announces RECELL® Data Demonstrating Statistically Significant Reduction in Donor Skin Requirements and Pain, Increased Patient Satisfaction and Improved Donor Scar Outcomes for Second-Degree Burn Patients
RECELL Device presentations include data from pivotal trial and health economic results showing 44 percent reduction in total treatment costs compared to standard of care AVITA Medical (ASX: AVH ) (OTCQX: AVMXY ) announced today that results from a pivotal clinical trial demonstrati...
Source: Business Wire
Date: April, 11 2018 20:48
AVITA Medical Announces Schedule for Six RECELL® Device Presentations at American Burn Association (ABA) 50th Annual Meeting
Clinical results demonstrate patient benefits and cost-effectiveness of RECELL Autologous Cell Harvesting Device in the treatment of severe burns AVITA Medical (ASX: AVH, OTCQX: AVMXY) announced today new data to be presented describing clinical and cost-savings advantages of RECEL...
Source: Business Wire
Date: April, 02 2018 21:59
AVITA Medical Announces RECELL® Health Economic Model to be Presented at ISPOR 23rd Annual International Meeting
Demonstrates cost-effectiveness of RECELL in the treatment of severe burns AVITA Medical (ASX: AVH, OTCQX: AVMXY) announced today that an abstract highlighting an economic model demonstrating the cost benefit of RECELL® in the treatment of burns has been accepted for presentation...
Source: Business Wire
Date: March, 25 2018 22:38
Week In Review: James Watson To Lead New Shenzhen Biopharma Research Center
Industry Developments James Watson, who co-discovered the double-helix structure of DNA in 1953, will lead a new international life science research center in the International Bio Valley, located in Shenzhen's Dapeng New Area. A groundbreaking ceremony was held last Friday with Dr. Watson i...
Source: SeekingAlpha
Date: March, 25 2018 09:31
AVITA Medical Announces MIHS Burn Center Press Conference Regarding RECELL® Treatment of Patient with Necrotizing Fasciitis (Flesh Eating Bacteria)
AVITA Medical (ASX – AVH, OTCQX: AVMXY) announced that Maricopa Integrated Health System (MIHS) Burn Center will hold a press conference today to highlight the recent treatment with RECELL® of a woman with necrotizing fasciitis, or flesh eating bacteria. The woman was treated wit...
Source: Business Wire
Date: March, 22 2018 00:53
AVITA Medical Announces Government Funded Clinical Trial of RECELL® in China
Also Announces that Major Hospital Will Host New Training Center for RECELL in Beijing AVITA Medical (ASX: AVH) (OTCQX: AVMXY) today announced the commencement of a randomized, controlled clinical trial of RECELL® in the treatment of deep partial-thickness (second-degree) burns i...
Source: Business Wire
Date: March, 19 2018 15:42
RenovaCare: Many Catalysts, Untold Downside
Nobody picked up RenovaCare’s phone yesterday, when TheStreetSweeper called. It seems like this half-a-billion-dollar company would have a secretary or assistant … or janitor … or somebody … around to answer the phone. RenovaCare ( OTCQB:RCAR ) is an over-...
Source: SeekingAlpha
Date: February, 12 2018 10:13

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-04-230.920.91750.940.91754,300
2018-04-220.920.91750.940.91754,300
2018-04-210.920.91750.940.91754,300
2018-04-200.920.91750.940.91754,300
2018-04-190.91860.920.96720.91866,523

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-04-192,0006,52330.6607Cover
2018-04-187,00010,90064.2202Short
2018-04-1729529,0611.0151Cover
2018-04-1643,48572,11360.3012Short
2018-04-1311,81128,57341.3362Short

* Short Mode

Short Analysis provided by Squeeze Report.


About Avita Medical Ltd. (OTC: AVMXY)

Logo for Avita Medical Ltd. (OTC: AVMXY)

Avita Medical s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. Our medical devices work by preparing a Regenerative Epithelial Suspension RES , an autologous suspension comprised of the patients own skin cells and wound healing factors that are necessary to regenerate natural healthy skin. This is then applied to the area to be treated. In all countries outside of Europe, our portfolio is marketed under the ReCell brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. ReCell is TGA registered in Australia, and CFDA cleared in China. In the United States, ReCell is an investigational device limited by federal law to investigational use. In Europe, our portfolio of medical device products received CE mark approval as three tailored product presentations, with three individual brand names. ReCell is designed for the treatment of burns and plastic reconstructive procedures ReGenerCell has been formulated for chronic wounds including leg and foot ulcers and ReNovaCell is tailored for aesthetic applications including the restoration of pigmentation.

 

 

 

Current Management

  • Michael Perry / CEO, Executive Director
  • Dale Sander / CFO
  • Timothy Rooney / Chief Admin. Officer
  • Lou Panaccio / Chairman
  • Louis Drapeau / NonExecutive Director
  • Suzanne Crowe / NonExecutive Director
  • Jeremy Curnock Cook / NonExecutive Director

Current Share Structure

  • Market Cap: $32,987,773 - 03/15/2018
  • Authorized: 838,989,992 - 08/30/2016
  • Issue and Outstanding: 673,219,854 - 12/31/2016

 


Recent Filings from (OTC: AVMXY)

Semi-Annual Report - Half Yearly Reports and Accounts
Filing Type: Semi-Annual Report - Half Yearly Reports and AccountsFiling Source: OTC Markets
Filing Date: February, 27 2018
Quarterly Report - Quarterly Report
Filing Type: Quarterly Report - Quarterly ReportFiling Source: OTC Markets
Filing Date: January, 30 2018
Annual Report - Avita Releases Annual Report to Shareholders
Filing Type: Annual Report - Avita Releases Annual Report to ShareholdersFiling Source: OTC Markets
Filing Date: October, 31 2017
Quarterly Report - Quarterly Report
Filing Type: Quarterly Report - Quarterly ReportFiling Source: OTC Markets
Filing Date: October, 30 2017
Annual Report - Avita Medical Limited Full Financial Report
Filing Type: Annual Report - Avita Medical Limited Full Financial ReportFiling Source: OTC Markets
Filing Date: September, 29 2017
Quarterly Report - Avita Medical Announces 4th Quarter 2017 Results
Filing Type: Quarterly Report - Avita Medical Announces 4th Quarter 2017 ResultsFiling Source: OTC Markets
Filing Date: July, 28 2017
Quarterly Report - Quarterly Report and CEO Shareholder Letter
Filing Type: Quarterly Report - Quarterly Report and CEO Shareholder LetterFiling Source: OTC Markets
Filing Date: April, 27 2017
Semi-Annual Report - Appendix 4D Half Yearl Report December 2016
Filing Type: Semi-Annual Report - Appendix 4D Half Yearl Report December 2016Filing Source: OTC Markets
Filing Date: February, 27 2017
Quarterly Report - CEO Share Letter and Quarterly Report
Filing Type: Quarterly Report - CEO Share Letter and Quarterly ReportFiling Source: OTC Markets
Filing Date: January, 30 2017
Annual Report - Concise Financial Report 2016
Filing Type: Annual Report - Concise Financial Report 2016Filing Source: OTC Markets
Filing Date: October, 28 2016

 

 


Daily Technical Chart for (OTC: AVMXY)

Daily Technical Chart for (OTC: AVMXY)


Stay tuned for daily updates and more on (OTC: AVMXY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: AVMXY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AVMXY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of AVMXY and does not buy, sell, or trade any shares of AVMXY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/

 

 

Release this Report to Investors

Via Email

Via Text

Important

If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us